Robert Fried serves as the Chief Executive Officer of NIAGEN BIOSCIENCE INC., a leading innovator in nicotinamide riboside (NR) technology and NAD+ precursor solutions for health and wellness applications. With over two decades of experience in the biotechnology and consumer health industries, Fried has held senior leadership roles at companies such as ChromaDex Corporation, where he previously advanced from Chief Operating Officer to President and CEO. His career also includes executive positions at Nutraceutical Corporation and other firms focused on dietary supplements and functional ingredients, where he honed expertise in regulatory affairs, supply chain management, and global commercialization. Under Fried's leadership, NIAGEN BIOSCIENCE INC. has achieved significant milestones, including the expansion of clinical research validating the efficacy of NIAGEN® (nicotinamide riboside chloride) in supporting cellular energy, healthy aging, and metabolic health. He spearheaded partnerships with major brands and research institutions, driving substantial revenue growth and securing intellectual property protections for proprietary NR formulations. Fried's strategic vision has positioned the company as a pioneer in the burgeoning NAD+ therapeutics market, with successful product launches in nutraceuticals, cosmetics, and emerging pharmaceutical applications. As CEO, Fried oversees all aspects of NIAGEN BIOSCIENCE INC.'s operations, from R&D and manufacturing to marketing and international distribution. Committed to evidence-based innovation, he continues to guide the company toward sustainable growth, emphasizing rigorous science, consumer safety, and collaborations that advance human healthspan.